Searchable abstracts of presentations at key conferences in endocrinology

ea0011p435 | Endocrine disruptors | ECE2006

Endocrine disruptors and idiopathic gynecomastia with aromatase gene polymorphism

Czajka IK , Zgliczynski S , Zgliczynski W

Gynecomastia is a benign enlargement of the male breast due to the imbalance between androgens and estrogens in the breast tissue. In up to 40% of cases no evident reasons could be found. This idiopathic gynecomastia may be caused by excess aromatisation within breast tissue. Aromatase is a key enzyme in estrogen biosynthesis. Mutations and polymorphisms of aromatase gene could lead to its overexpression. Some endocrine disruptors - chemicals that interfere with hormone functi...

ea0070ep279 | General Endocrinology | ECE2020

Myasthenia gravis during anti PD-1 therapy

Jankowska Katarzyna , Zgliczynski Wojciech

A 66-year-old patient was diagnosed with lung cancer. In the interview, smoking for 40 years, about 20 cigarettes/day. Due to the intensifying cough, an x-ray of the chest was performed, a large tumor (12 cm) of the mediastinum and the right cavity was found. In the histopathological examination squamous cell carcinoma. Stage T4 N2 M0. Due to tumor inoperability, the patient was qualified for sequential chemo-radiotherapy. He received 3 cycles of chemotherapy (navelbin and cis...

ea0029p171 | Bone & Osteoporosis | ICEECE2012

Denosumab increases BMD in primary hyperparathyroidism

Misiorowski W. , Zgliczynski W.

Primary hyperparathyroidism (PHPT) is often associated with reduced bone mineral density (BMD). An open-labeled, prospective trial was conducted to determine whether denosumab 60 mg subcutaneously given every 6 months, maintains or improves BMD in patients with PHPT.Six patients had symptomatic PHPT and met surgical guidelines however refused surgery, and twelve patients had mild PHPT, asymptomatic except low BMD. The primary outcome index, BMD, was meas...

ea0026p277 | Pituitary | ECE2011

Minimal active acromegaly may be effectively treated by prolonged injections of octreotide LAR

Zdunowski P , Zgliczynski W

In acromegaly, an excessive GH secretion by pituitary adenoma, minimal active disease may be defined as slow progression of characteristic signs and symptoms at presence of slightly elevated or normal IGF1 levels and lack of GH suppression after glucose load. Nadir post-glucose GH level defining active disease is under permanent discussion and depends on assessment methods. IGF1 reference range is wide, must be age-adjusted and often is sex-dependent. From mid-00’s excess...

ea0016p260 | Diabetes and cardiovascular diseases | ECE2008

The high prevalence of testosterone deficiency syndrome and erectile dysfunctions in the aging men with diabetes mellitus type 2

Rabijewski Michal , Zgliczynski Wojciech

Objective: The aim of the study was to determine the prevalence of subclinical late-onset hypogonadism (SLOH) and erectile dysfunctions in the elderly men with diabetes type 2.Material and methods: We investigated 51 men mean aged 68.3 years with diabetes type 2 according ADA recommendations. Androgens concentrations, BMI, HbA1C were measured. All of men were treated with oral antidiabetic drugs or insulin. LOH was expected on the basis of low testostero...

ea0016p261 | Diabetes and cardiovascular diseases | ECE2008

The influence of testosteone replacement therapy on erectile dysfunctions in aging men with testosterone deficiency and diabetes mellitus type 2

Rabijewski Michal , Zgliczynski Wojciech

Objective: The role of testosterone in the anatomy and physiology of erection is becoming clear. Erectile dysfunctions (ED) are very common observed in men with diabetes mellitus type 2 (DM2). The aim of the study was to determine the efficacy of testosterone adminisartions in elderly men with ED and DM2.Material and methods: We investigated 41 men mean aged 65.4 years with late onset hypogonadism according Polish Endocrine Society recommendations and DM...

ea0014p601 | (1) | ECE2007

Glucose resistance in acromegaly is reversible during somatostatin analogues treatment

Zdunowski Piotr , Zgliczynski Wojciech

Background: Insulin resistance leading to glucose intolerance and even diabetes mellitus is common in acromegaly and is partially caused by pathological high concentrations of growth hormone (GH) and somatomedin C (IGF-1). On the other hand, somatostatin analogues, common treatment option, can cause inhibition of insulin secretion and glucose tolerance disturbances.Aim: Of the study was to determine impact of prolonged somatostatin analogues administrati...

ea0081p149 | Pituitary and Neuroendocrinology | ECE2022

Clinical aspects of pituitary tumors in patients with Multiple Endocrine Neoplasia Type 1: results from the preliminary study

Zgliczynski Stanislaw , Kochman Magdalena , Zgliczynski Wojciech , Bednarczuk Tomasz

Introduction: Multiple Endocrine Neoplasia Type 1 (MEN1) is a rare disease inherited in an autosomal dominant pattern, caused by mutations in the MEN1 gene. The cardinal components of this syndrome are: primary hyperparathyroidism (PHPT), gastroenteropancreatic neuroendocrine tumors (NETs) and pituitary tumors.Aim: The aim of the study was to evaluate clinical features of MEN1 patients under care of two teritiary centers in Warsaw, Poland with special fo...

ea0070aep818 | Reproductive and Developmental Endocrinology | ECE2020

Epidemiology, clinical features and management of multiple endocrine neoplasia Type 1 – a two-center study

Zgliczynski Stanislaw , Bednarczuk Tomasz , Rogozik Natalia , Kochman Magdalena , Wojciech Zgliczynski

Background: Multiple Endocrine Neoplasia Type 1 (MEN1) is a rare, autosomal dominant disease characterized by the coexistence of at least two of the following: primary hyperparathyroidism (PHPT), neuroendocrine tumors (NET) and pituitary tumors. The aim of the study was to evaluate epidemiology, clinical features and management of MEN1 patients in two referral centers in Warsaw, Poland.Material and Methods: Study group consisted of 52 patients, aged from...

ea0070aep634 | Pituitary and Neuroendocrinology | ECE2020

Unusual case of women suffering from aggressive silent thyrotropinoma treated with somatostatin analogues during pregnancy

Zgliczynska Magdalena , Majos Agnieszka , Stelmachowska-Banas Maria , Zgliczynski Wojciech

Background: Thyroid-stimulating hormone (TSH) expressing tumors are one of the rarest pituitary adenomas and comprises 0.5–2% of all cases. To our knowledge, only four cases of thyrotropinoma in a pregnant women have been reported up to date.Case presentation: We present a case of 24-year old women who reported to gynecologist due to secondary amenorrhea and severe headaches. Commissioned laboratory test showed, among others, prolactin 31.0 ng/ml a...